Social Media Ideas for Hfarx

Latest updates for Hfarx

Fresh curated links around HFARX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

seekingalpha.com /1 month ago

HeartFlow, Inc. (HTFL) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

Read source

pharmexec.com /3 days ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Hibsago]]>

Read source

pharmexec.com /3 weeks ago

<![CDATA[Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data]]>

Read source

pharmexec.com /3 weeks ago

<![CDATA[Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909]]&gt...

Read source

seekingalpha.com /1 month ago

Axsome rises on Auvelity prescription data

Read source

seekingalpha.com /1 month ago

Janus Henderson Developed World Bond Fund Q2 2026 Commentary

Read source

seekingalpha.com /1 week ago

XPH: Healthcare Sector Dashboard For October

Read source

pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Fayuvi]]>

Read source

seekingalpha.com /1 month ago

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment...

Read source

seekingalpha.com /1 month ago

Hafnia Limited (HAFN) Q2 2026 Earnings Call Transcript

Read source

fool.com /1 month ago

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.

Read source

fool.com /2 weeks ago

Better Pharma ETF: iShares IHE vs. State Street XPH

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

Read source

seekingalpha.com /1 month ago

Fenix Resources Limited (FEXRF) Q4 2026 Earnings Call Transcript

Read source

fool.com /1 month ago

American Healthcare REIT Executive Sells 2,000 Shares for $111,000

Foster executed the sale under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, leaving him with 51,617 shares valued at $2.9 million.

Read source

seekingalpha.com /1 week ago

Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout

Read source

seekingalpha.com /1 month ago

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment...

Read source

seekingalpha.com /1 month ago

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

Read source

investing.com /1 month ago

Faron Pharmaceuticals receives major holding notification

Read source

seekingalpha.com /1 month ago

Hartford Conservative Allocation Fund Q2 2026 Commentary

Read source

seekingalpha.com /3 weeks ago

Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher

Read source

seekingalpha.com /3 weeks ago

XHE: Health Care Equipment Likely To Underperform Amid Higher Rates (Downgrade)

Read source

seekingalpha.com /1 month ago

HMAX:CA: Core Holding Pumping Out 11%+ With Low Risk

Read source

seekingalpha.com /1 month ago

Harbor Mid Cap Value Fund Q2 2026 Commentary

Read source

seekingalpha.com /1 month ago

Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.